Power Mech shares up 10% on orders worth Rs 1,311 crore

The share touched its 52-week high Rs 800 and 52-week low Rs 310 on 11 February 2020 and 27 May 2020, respectively.

Power Mech Projects share price gained nearly 10 percent intraday on September 3 after the company received a letter of intent/L1 intimation for the work orders worth Rs 1,311.70 crore.

The work orders include a project on EPC basis in the state of Karnataka worth Rs 555.13 crore from NHAI. This is a joint venture between Power Mech and SRC Infra in the ratio of Power Mech 60 percent and SRC infra 40 percent respectively.

The other project is widening and upgradation to 2 lanes with paved shoulder configuration and geometric improvement on Aizawl-Tuipang Section of NH-54 in the State of Mizoram (Package-7) worth Rs 446.40 crore from NHIDCL. This is a JV between Power Mech and SRC Infra in the ratio of Power Mech 74 percent and SRC infra 26 percent respectively.

It also got a contract worth Rs 176.17 crore from LMB.

The other contracts include doubling of BVRM NS section on Vijayawada division of south-central railway in Andhra Pradesh which is worth Rs 35 crore and Yard Modification works at MIM as per the revised ESP in connection with doubling of the railway line between Gudivada-Machilipatnam stations of Vijayawada worth Rs 32 crore from Rail Vikas Nigam.

It received O&M of Ash Handling Plant of 3x660MW Talwandi Sabo Power in Punjab worth Rs 21 crore from Steag and balance Misc civil works worth Rs 46 crore from Rail Vikas Nigam.

At 11:43 hrs Power Mech Projects was quoting at Rs 463.00, up Rs 29.10, or 6.71 percent on the BSE.

The share touched its 52-week high Rs 800 and 52-week low Rs 310 on 11 February 2020 and 27 May 2020, respectively.

Currently, it is trading 42.13 percent below its 52-week high and 49.35 percent above its 52-week low.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog